---
schema_version: "secwatch.filing_event.v1"
accession: "0001847367-25-000010"
form_type: "8-K"
ticker: "ALMS"
cik: "0001847367"
company_name: "ALUMIS INC."
filed_at: "2025-03-19T23:59:59+00:00"
generated_at: "2026-05-24T12:08:29.258569+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alumis 2024 net loss $294.2M, cash $288.3M; ACELYRIN merger expected Q2 2025

## Summary
- Net loss of $294.2M in 2024 vs $155.0M in 2023; R&D expenses rose to $265.6M from $137.7M.
- Cash, cash equivalents and marketable securities of $288.3M as of Dec 31, 2024.
- All-stock merger with ACELYRIN; pro forma cash ~$737M; Alumis stockholders to own ~55% on diluted basis.
- Phase 3 ESK-001 psoriasis topline data expected Q1 2026; Phase 2 MS trial for A-005 to start 2H 2025.
- Appointed Jack Danilkowicz as CCO and Sara Klein as CLO to bolster late-stage capabilities.

## SEC filing metadata
- accession: 0001847367-25-000010
- form_type: 8-K
- ticker: ALMS
- cik: 0001847367
- company_name: ALUMIS INC.
- filed_at: 2025-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847367/000184736725000010/0001847367-25-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847367/000184736725000010/tmb-20250319x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847367-25-000010
- JSON: https://secwatch.observer/filing/0001847367-25-000010.json
- Plain text: https://secwatch.observer/filing/0001847367-25-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.